Precision BioSciences, Inc. (NASDAQ:DTIL) Stock Has Consensus Target Price of $32.25

Precision BioSciences, Inc. (NASDAQ:DTIL) has been assigned an average rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $32.25.

DTIL has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Precision BioSciences from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a research report on Tuesday, November 3rd. Finally, HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd.

Precision BioSciences Trading Down 12.1%

Precision BioSciences stock opened at $8.04 on Friday. Precision BioSciences has a one year low of $3.53 and a one year high of $11.29. The company has a debt-to-equity ratio of 0.43, a current ratio of 10.47 and a quick ratio of 10.47. The business has a fifty day moving average of $7.01 and a two-hundred day moving average of $6.71.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.57. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 56.69%. Research analysts forecast that Precision BioSciences will post -2.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Precision BioSciences

Several institutional investors and hedge funds have recently made changes to their positions in DTIL. Corient Private Wealth LP raised its position in Precision BioSciences by 70.4% during the second quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock worth $1,926,000 after acquiring an additional 101,206 shares during the last quarter. Octagon Capital Advisors LP grew its position in shares of Precision BioSciences by 16.6% in the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after purchasing an additional 318,737 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after buying an additional 93,258 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in Precision BioSciences during the 1st quarter valued at $3,289,000. Finally, Bank of America Corp DE increased its position in Precision BioSciences by 167.6% during the first quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after buying an additional 17,172 shares in the last quarter. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases. The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.